Faculty
Videos Introducing Keio Research
Establishment of New Pharmacotherapy Options Based on Drug Efficacy Evaluation and Adverse Event Analysis
The Division of Pharmacodynamics conducts research, aiming to establish new pharmacotherapy options by evaluating drug efficacy or the therapeutic and adverse effects of drugs.
To maximize their effectiveness while avoiding related adverse events as much as possible, the division analyses influencing factors, and clarifies optimal drug options and administration methods for each patient.
It also establishes new treatment methods by identifying new drug activities and developing new dosage forms. Furthermore, with a view to obtaining evidence that is useful for medical services, it identifies issues to be addressed (such as drug-drug interactions), and expands clinical and basic research.
The division aims to nurture clinical pharmacists to truly contribute to medical services and researchers with the ability to develop drugs needed in such services through research activities.
Figure. Voriconazole (VRCZ) trough concentration and logistic regression model for hepatotoxicity. The estimated probability of hepatotoxicity at VRCZ trough concentrations of 2mg/L and 4mg/L was 1.6% and 21.6%, respectively
Figure. Relationships for Acinetobacter baumannii ATCC 19606 between the log10CFU/thigh at 24 h and the pharmacokinetic/pharmacodynamic indices. Sulbactam showed time-dependent bactericidal activity, and was sufficiently bactericidal when an fT>MIC of >60% against A. baumannii thigh infection was achieved.